Intellia Therapeutics Inc

News & Events zu Intellia Therapeutics Inc (NTLA)

$12.870

-0.236 (-1.83%)Zum Schluss

NTLA-News

NTLA-Events

8/6 08:00

Intellia Q2 Revenue $7.66M, Below Consensus

Reports Q2 revenue $7.66M, consensus $12.98M. "The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in hereditary angioedema," said John Leonard, Intellia President and Chief Executive Officer. "These data serve as strong validation for in vivo gene editing and lonvo-z's potential to transform the treatment paradigm for patients who are burdened by this disease."

6/17 12:30

Intellia Therapeutics Stock Rises 12.9% to $16.43

Intellia Therapeutics is up 12.9%, or $1.88 to $16.43.

6/17 10:30

Intellia Therapeutics Stock Rises 10.7% to $16.11

Intellia Therapeutics is up 10.7%, or $1.56 to $16.11.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten